Quantum computing firm IonQ (IONQ) announced an investment partnership on Monday with the Center for Commercialization of Regenerative Medicine, aimed at using hybrid quantum and quantum-AI technologies in medicine.
The partnership will aid the development of next-generation of therapeutics, bringing together CCRM’s new quantum-biotech initiatives, with IonQ as the core tech partner.
Also included in the partnership will be a focus on bioprocess optimization, disease-modeling workflows, and quantum enhanced simulation to support the design and manufacturing of advanced therapies, IonQ added. Initial projects will be in Canada and Sweden next year.
“IonQ’s quantum technologies are poised to reshape industries, and health care is one of the most exciting frontiers,” said IonQ CEO and Chairman Niccolo de Masi in a statement. “Together with CCRM and its global partners, we will identify, test, and deploy breakthrough applications that will transform therapeutic development, biomanufacturing, and delivery for patients across the globe.”
IonQ shares fell 2% in premarket trading on Monday.
